A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

March 14, 2023

Study Completion Date

March 14, 2023

Conditions

OverweightObesity

Interventions

DRUG

Formulation A (PF-07081532 20 mg plus 60 mg)

Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet

DRUG

Formulation B (PF-07081532 80 mg)

Formulation B: administered as a 80 mg immediate release tablet

Trial Locations (1)

New Haven Clinical Research Unit, New Haven